10X Genomics Q4 prelim revenue beats on consumables unit strength

10x Genomics

12/01/2026 05:38

Overview

Life science tech firm's preliminary Q4 revenue rises, beating analyst expectations

Consumables revenue grew 6% yr/yr, while instruments revenue fell 36% yr/yr

Preliminary results subject to adjustment as financial statements are finalized

Outlook

Company did not provide specific guidance for future quarters or the full year

Result Drivers

CONSUMABLES GROWTH - Consumables revenue grew 6% year-over-year, driven by a 14% increase in Spatial consumables

INSTRUMENTS DECLINE - Instruments revenue decreased 36% year-over-year, with both Single Cell and Spatial instruments contributing to the decline

SERVICES AND LICENSE REVENUE - Services and license revenue grew 23% year-over-year, despite a slight sequential decrease

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$166 mln
$150.80 mln (14 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 13 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for 10X Genomics Inc is $18.00, about 12% below its January 9 closing price of $20.46

Press Release: ID:nPnbRBZ8Fa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)